Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
61 Cards in this Set
- Front
- Back
- 3rd side (hint)
4 Common subtypes of fungi
|
1. Yeasts
2. Moulds 3. Dimorphic Fungi 4. Dermatophytes |
|
|
Name the subtypes of the 4 common subtypes of fungi
|
1. Yeasts:
a. Candida b. Cryptococcus 2. Moulds a. Aspergillus b. Fusarium (exception: in blood, not tissues) c. Zygomycetes 3. Dimorphic Fungi a. Histoplasma b. Blastomyces c. Coccidoides 4. Dermatophytes a. Trichophyton b. Microsporon |
|
|
Trichophyton
|
Dermatophyte
|
|
|
Microsporon
|
Dermatophyte
|
|
|
Coccidoides
|
Dimorphic fungi
|
|
|
Histoplasma
|
Dimorphic fungi
|
|
|
Blastomyces
|
Dimorphic fungi
|
|
|
Aspergillus
|
Moulds
|
|
|
Fusarium
|
Moulds
|
|
|
Zygomycetes
|
Moulds
|
|
|
Candida
|
Yeasts
|
|
|
Cryptococcus
|
Yeasts
|
|
|
Antifungal Agents
|
Griseofulvin
Polyenes (Nystatin & Amphotericin B) Amphotericin B 5FC Terbinafine Azoles Echinocandins (caspofungin, micafungin, anidulafungin) |
|
|
Griseofulvin
|
Common dosing for adults with normal renal function
• Microsize (Grifulvin V®) – 500-1000 mg/day in single or divided doses • Ultramicrosize (Gris-PEG®) – 330-375 mg/day in single or divided doses MOA – Inhibits fungal cell mitosis and nucleic acid synthesis; binds to human keratin making it resistant to fungal invasion (fungistatic) SOA – Dermatophytes PK • Eliminated hepatically • Take with a fatty meal to increase absorption ADRs – Photosensitivity, headaches, dizziness, drowsiness, rash, urticaria DIs – Weak inducer of CYP 1A2, 2C8/9, 3A4 • May decrease the effect of warfarin and oral contraceptives • Barbiturates may decrease griseofulvin concentrations • Disulfiram like reaction with alcohol |
|
|
Nystatin
|
Common dosing
• Oral suspension – 400,000-600,000 units swish and swallow QID • Lozenge – 200,000-400,000 units QID • Vaginal tablet – 100,000 unit tablet every 24 hrs • Topical – apply topically BID-TID • No IV b/c too much toxicity MOA – Binds to ergosterol in fungal cell membrane → increased cell membrane permeability → loss of intracellular contents → cell death (fungicidal) Spectrum of Activity (SOA) – Candida spp. only PK – Poor oral absorption ADRs – Contact dermatitis with topical application on skin Give Nystatin lozenge or the swish and swallow kind to someone who has thrush |
|
|
Which antifungal is eliminated hepatically?
|
Griseofulvin,
terbinafine, ketoconazole, itraconazole, voriconazole, posaconazole, caspofungin, and micafungin are eliminated hepatically |
|
|
Which antifungal causes disulfiram-ilke reaction with alcohol?
|
Griseofulvin
|
|
|
Which drug class decreases griseofulvin's concentrations
|
Barbiturates
|
|
|
Which CYP450 enzymes does griseofulvin induce?
|
CYP1A2
CYP2C8/9 CYP3A4 T/f decreases effectiveness of warfarin and oral contraceptives |
|
|
Nystatin is available in 4 formulations:
|
Oral suspension, lozenge, vaginal tablet, topical
|
|
|
What is the MOA of griseofulvin?
|
Inhibits fungal cell mitosis and nucleic acid synthesis. Binds to human keratin making it resistant to fungal invasion (fungistatic).
|
|
|
What is the SOA of griseofulvin?
|
Dermatophytes
|
|
|
What is the MOA of nystatin?
|
Binds to ergosterol in fungal cell membrane -> increased cell permeability -> loss of intracellular contents -> cell death (fungicidal)
|
|
|
What is the SOA of nystatin?
|
Candida
|
|
|
Amphotericin B
|
• Amphotericin B deoxycholate (conventional, Fungizone®)
o Common dosing – 0.25-1 mg/kg IV every 24 hrs • Amphotericin B lipid complex (ABLC, Abelcet®) o Common dosing – 5 mg/kg IV every 24 hrs • Amphotericin B cholesteryl sulfate (colloidal dispersion, ABCD, Amphotec®) o Common dosing – 3-6 mg/kg IV every 24 hrs • Liposomal amphotericin B (AmBisome®) o Common dosing – 3-5 mg/kg IV every 24 hrs Don’t need to remember doses but know that the doses change according to the formulation! MOA – Binds to ergosterol in fungal cell membrane → increased cell membrane permeability → loss of intracellular contents → cell death (fungicidal) SOA – Very broad spectrum! Yeasts (not C. lusitaniae), Aspergillus spp. (except A. terreus, variable for A. flavus), Zygomycetes, dimorphic fungi PK • Eliminated by the reticuloendothelial system • Deoxycholate has good CNS activity despite poor CNS penetration (clinically useful) ADRs “Ampho-terrible” • Infusion related toxicities (lower incidence with liposomal, similar incidence with ABCD) o Fever, chills, rigors, myalgias, nausea, headaches o Tolerance does develops after 1-2 doses o Prevention/Management of infusion related toxicities Slow down the rate of infusion (usually infused over 2-6 hrs) Give as a continuous infusion (but this is tricky b/c then needs separate IV line, check compatibility with other medications) Premedications 30-60 minutes prior to administration • APAP, aspirin, NSAID – prevent fevers, myalgias • Diphenydramine – causes drowsiness, blocks histamine release • Hydrocortisone – interferes with cytokine pathway • Typically give APAP plus diphenhydramine Symptomatic treatment • Meperidine – to treat rigors • Chlorpromazine, other antiemetics – to reduce nausea • Nephrotoxicity (lower incidence with lipid formulations but will occur with any formulation) o Glomerular: increased BUN and serum creatinine o Tubular: K+ and/or Mg2+ wasting o Prevention/Management 0.5-1 L normal saline 30-60 min prior to every dose Replacement of electrolytes • Others: phlebitis, anemia, lipid formulations may cause a pulmonary reaction, liposomal may cause hyperbilirubinemia DIs • Other nephrotoxins (e.g. aminoglycosides, vancomycin, cyclosporine) • Incompatible with many IV solutions – risk of precipitation |
|
|
There are four formulations of Amphotericin B:
|
1. Amphotericin B deoxycholate (conventional, Fungizone®)
o IV 2. Amphotericin B lipid complex (ABLC, Abelcet®) o IV 3. Amphotericin B cholesteryl sulfate (colloidal dispersion, ABCD, Amphotec®) o IV 4. Liposomal amphotericin B (AmBisome®) o IV |
|
|
What is the MOA of amphotericin B?
|
Binds to ergosterol in fungal cell membrane → increased cell membrane permeability → loss of intracellular contents → cell death (fungicidal)
|
|
|
What is the SOA of amphotericin B?
|
very broad spectrum!
Yeasts (not C. lusitaniae), Aspergillus spp. (except A. terreus, variable for A. flavus), Zygomycetes, dimorphic fungi |
|
|
Which drug is eliminated by the reticuloendothelial system?
|
Amphotericin B
|
|
|
Why is Amphotericin B called "Ampho-terrible"?
|
• Infusion related toxicities (lower incidence with liposomal, similar incidence with ABCD)
o Fever, chills, rigors, myalgias, nausea, headaches o Tolerance does develop after 1-2 doses • Nephrotoxicity (lower incidence with lipid formulations but will occur with any formulation) o Glomerular: increased BUN and serum creatinine o Tubular: K+ and/or Mg2+ wasting • Others: phlebitis, anemia, lipid formulations may cause a pulmonary reaction, liposomal may cause hyperbilirubinemia |
|
|
Meperidine
|
treats rigors.
Rigors is one of the infusion-related toxicities associated with Amphotericin B infusion. |
|
|
What drugs interact with amphotericin B?
|
Other nephrotoxins (aminoglycosides, vancomycin, cyclosporine)
Incompatible with many IV solutions b/c of risk of precipitation (give it in its own separate IV line) |
|
|
Antimetabolite- Flucytosine
|
Common dosing – 25-37.5 mg/kg PO Q 6 hrs
• Increase dosing interval for renal dysfunction based on Clcr MOA – Inhibits fungal RNA, DNA, and protein synthesis SOA – Yeasts (used with other agents only, resistance develops rapidly when used alone) Never give Fluocytosine alone! Usually given in combination with Amphotericin B for pneumococcal meningitis b/c it has excellent CNS penetration PK • Excellent CNS penetration • Eliminated renally • Therapeutic range is 25-100 mcg/mL (to decrease risk of bone marrow suppression) ADRs – Dose-related bone marrow suppression, GI upset, rash, photosensitivity, increased BUN/serum creatinine DIs • Other bone marrow suppressive agents (zidovudine, chemotherapeutic drugs, TMP/SMX) • Caution with nephrotoxins due to risk of accumulating flucytosine |
|
|
What is the SOA of Flucytosine?
|
Yeasts (but must use 5FC with other agents! Cannot be used for monotherapy.)
|
|
|
How is 5FC eliminated?
|
renally
|
|
|
What drugs interact with 5-FC?
|
• Other bone marrow suppressive agents (zidovudine, chemotherapeutic drugs, TMP/SMX)
• Caution with nephrotoxins due to risk of accumulating flucytosine |
|
|
Allylamine- Terbinafine (Lamisil)
|
Common dosing
• Oral o Not recommended if Clcr < 50 mL/min o Not recommended in chronic or active liver disease • Topical – apply topically BID MOA – Inhibition of squalene epoxidase → decreased ergosterol → increased cell membrane permeability → loss of intracellular contents → cell death (fungicidal) SOA – Dermatophytes, Candida spp. PK • Eliminated hepatically • Distributed mostly to the skin and skin structures ADRs – Headache, dizziness, rash, pruritus, GI upset, taste disturbance, visual disturbance, LFT elevations, hepatitis DIs • CYP 2D6 inhibitor – may increase concentrations of tricyclic antidepressants, cyclosporine, theophylline, warfarin • Rifampin may induce terbinafine metabolism • Cimetidine may inhibit terbinafine metabolism |
|
|
Terbinafine can be administered ____ and ____.
|
orally and topically.
|
|
|
What is the MOA of terbinafine?
|
Inhibition of squalene epoxidase → decreased ergosterol → increased cell membrane permeability → loss of intracellular contents → cell death (fungicidal)
|
|
|
How is terbinafine eliminated?
|
Hepatically
|
|
|
What drugs do terbinafine interact with?
|
it is a CYP2D6 inhibitor so it may increase concentrations of TCAs, cyclosporine, theophylline, warfarin.
Rifampin might induce terbinafine metabolism while cimetidine may inhibit terbinafine metabolism. |
|
|
Azoles-name some of the topical azoles.
|
Clotrimazole, econazole, miconazole, butoconazole, ticonazole, terconazole
|
|
|
What dosage forms do topical azoles come in?
|
Topical azole dosage forms:
Vaginal tabs, creams, or suppositories Topical creams, solutions, and sprays for the skin, Oral troches |
|
|
Azoles- name some of the Systemic Azoles
|
Ketoconazole
Fluconazole (Diflucan) Itraconazole Voriconazole Posaconazole |
|
|
Ketoconazole comes in 3 forms:
|
Oral, topical, shampoo
|
|
|
Fluconazole comes in 2 forms:
|
IV & PO
|
|
|
Itraconazole comes in:
|
PO only
|
|
|
Voriconazole comes in 2 forms:
|
IV & PO
|
|
|
Posaconazole comes in:
(See hint) |
PO. (take with a fatty meal)
|
Remember that POsaconazole is PO only
|
|
SOA of topical azoles
|
Candida (yeasts), dermatophytes
|
|
|
SOA of systemic azoles
|
See notes p.10
|
|
|
Which is the broadest spectrum azole?
|
Posaconazole
|
|
|
Which two azoles have excellent oral BA as well as CNS penetration?
|
Fluconazole and voriconazole
|
|
|
How are the systemic azoles eliminated?
|
Ketoconazole, Itraconazole, Voriconazole, and posaconazole are all eliminated hepatically.
Exception is fluconazole, renally. |
|
|
The order of CYP3A4 inhibition in decreasing order
|
keto > itra ≥ vori ≥ posa > flu
(But later she wrote that Keto is not included in this?? Which one is correct?) |
|
|
Echinocandins include:
|
Caspofungin, micafungin, Anidulafungin
|
|
|
MOA of Echinocandins
|
Inhibit the synthesis of Beta (1,3) D glucan, an essential part of the fungal cell wall (fungicidal)
|
|
|
SOA of echinocandins
|
Candida (variable for parapsilosis), Aspergillus
|
|
|
How are the echinocandins eliminated?
|
Caspofungin and micafungin-hepatic
Anidulafungin - nonenzymatic degradation |
|
|
DIs of Echinocandins
|
• Rifampin, phenytoin, carbamazepine, dexamethasone, efavirenz, and nevirapine may induce caspofungin metabolism
o May need to increase dose of caspofungin to 70 mg IV every 24 hrs • Cyclosporine may increase caspofungin concentrationsª • Caspofungin may decrease tacrolimus concentrationsª • Micafungin may increase sirolimus and nifedpine concentrationsª ª but these are not very clinically significant as compared to azole drug interactions |
|
|
Which antifungal(s) is/are effective against Dermatophytes?
|
Griseofulvin & Terbinafine (Lamisil)
|
|